de Jong M - Search Results

1

Radiation dose distribution in human kidneys by octreotides in peptide receptor radionuclide therapy.

Konijnenberg M, Melis M, Valkema R, Krenning E, de Jong M. Konijnenberg M, et al. Among authors: de jong m. J Nucl Med. 2007 Jan;48(1):134-42. J Nucl Med. 2007. PMID: 17204710 Free article.

2

Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience.

Valkema R, De Jong M, Bakker WH, Breeman WA, Kooij PP, Lugtenburg PJ, De Jong FH, Christiansen A, Kam BL, De Herder WW, Stridsberg M, Lindemans J, Ensing G, Krenning EP. Valkema R, et al. Among authors: de jong m, de jong fh, de herder ww. Semin Nucl Med. 2002 Apr;32(2):110-22. doi: 10.1053/snuc/2002.31025. Semin Nucl Med. 2002. PMID: 11965606 Clinical Trial.

3

Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.

De Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman WA, Bakker WH, Smith C, Pauwels S, Krenning EP. De Jong M, et al. Semin Nucl Med. 2002 Apr;32(2):133-40. doi: 10.1053/snuc.2002.31027. Semin Nucl Med. 2002. PMID: 11965608 Review.

4

New advances in peptide receptor radionuclide therapy.

de Jong M, Krenning E. de Jong M, et al. J Nucl Med. 2002 May;43(5):617-20. J Nucl Med. 2002. PMID: 11994523 Free article. No abstract available.

5

Preclinical comparison of (111)In-labeled DTPA- or DOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapy.

Breeman WA, de Jong M, Erion JL, Bugaj JE, Srinivasan A, Bernard BF, Kwekkeboom DJ, Visser TJ, Krenning EP. Breeman WA, et al. Among authors: de jong m. J Nucl Med. 2002 Dec;43(12):1650-6. J Nucl Med. 2002. PMID: 12468515 Free article.

6

Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine.

Rolleman EJ, Valkema R, de Jong M, Kooij PP, Krenning EP. Rolleman EJ, et al. Among authors: de jong m. Eur J Nucl Med Mol Imaging. 2003 Jan;30(1):9-15. doi: 10.1007/s00259-002-0982-3. Epub 2002 Oct 29. Eur J Nucl Med Mol Imaging. 2003. PMID: 12483404 Clinical Trial.

7

Peptide receptor radionuclide therapy in vitro using [111In-DTPA0]octreotide.

Capello A, Krenning EP, Breeman WA, Bernard BF, de Jong M. Capello A, et al. Among authors: de jong m. J Nucl Med. 2003 Jan;44(1):98-104. J Nucl Med. 2003. PMID: 12515882 Free article.

8

Radiolabelled peptides for tumour therapy: current status and future directions. Plenary lecture at the EANM 2002.

de Jong M, Kwekkeboom D, Valkema R, Krenning EP. de Jong M, et al. Eur J Nucl Med Mol Imaging. 2003 Mar;30(3):463-9. doi: 10.1007/s00259-002-1107-8. Epub 2003 Feb 5. Eur J Nucl Med Mol Imaging. 2003. PMID: 12569416 Review.

9

Anti-tumor effect and increased survival after treatment with [177Lu-DOTA0,Tyr3]octreotate in a rat liver micrometastases model.

Breeman WA, Mearadji A, Capello A, Bernard BF, van Eijck CH, Krenning EP, de Jong M. Breeman WA, et al. Among authors: de jong m. Int J Cancer. 2003 Apr 10;104(3):376-9. doi: 10.1002/ijc.10952. Int J Cancer. 2003. PMID: 12569562

10

Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities.

Breeman WA, De Jong M, Visser TJ, Erion JL, Krenning EP. Breeman WA, et al. Among authors: de jong m. Eur J Nucl Med Mol Imaging. 2003 Jun;30(6):917-20. doi: 10.1007/s00259-003-1142-0. Epub 2003 Apr 4. Eur J Nucl Med Mol Imaging. 2003. PMID: 12677301

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,155 results

Search Page

Filters